John Kedora, MD
Vascular Surgery · Dallas, TXNPI 1902015043
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Shape Memory Medical Inc. at 39.3% of the total. 2025 is the largest year on record at $5,423, more than ten times the $296 reported in 2019.
Across 159 payments — averaging $60.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shape Memory Medical Inc.$4K
- Penumbra, Inc.$1K
- Silk Road Medical, Inc.$759
- Medtronic$466
- Inari Medical, Inc.$352
- Johnson & Johnson$311
- plus $3K from 35 others
Across 31 payments — averaging $2991.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shape Memory Medical Inc.$93K
What the payments were for
- Consulting fees$2,80029%
- Travel & lodging$1,48915%
- Food & beverage$5,35356%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shape Memory Medical Inc. | 7 | $3,786 |
| Penumbra, Inc. | 5 | $1,349 |
| Silk Road Medical, Inc. | 12 | $759 |
| Medtronic(2 entities) | 14 | $466 |
| Inari Medical, Inc. | 5 | $352 |
| Johnson & Johnson | 18 | $311 |
| Endologix LLC | 4 | $310 |
| Stryker | 11 | $244 |
| Terumo Medical Corporation | 2 | $165 |
| Angiodynamics, Inc. | 8 | $164 |
| Axogen | 6 | $153 |
| KCI USA, Inc. | 1 | $125 |
| Heartflow, Inc. | 1 | $110 |
| Lemaitre Vascular, Inc. | 4 | $109 |
| Abbott | 5 | $101 |
| Imperative Care, Inc | 3 | $91 |
| Bolton Medical Inc | 3 | $85 |
| Cardiva Medical, Inc. | 1 | $83 |
| Smith+Nephew | 5 | $78 |
| Reflow Medical Inc | 4 | $72 |
| Integra Lifesciences Corporation | 3 | $62 |
| Bard Peripheral Vascular, Inc. | 3 | $60 |
| Cardiovascular Systems Inc. | 4 | $58 |
| Surmodics, Inc. | 2 | $54 |
| Cvrx, Inc. | 2 | $54 |
| Cashflow Solutions, LLC | 4 | $53 |
| Sirtex Medical Inc | 3 | $50 |
| Pfizer | 3 | $46 |
| Baxter Healthcare | 2 | $41 |
| Humacyte Global, Inc. | 1 | $32 |
| Philips North America LLC | 2 | $31 |
| Contego Medical, Inc | 2 | $30 |
| Convatec Inc. | 1 | $27 |
| Davol Inc. | 1 | $24 |
| Biocompatibles, Inc. | 1 | $23 |
| Inspiremd Ltd | 1 | $16 |
| Teleflex LLC | 1 | $14 |
| Nevro Corp. | 1 | $14 |
| Neuros Medical, Inc. | 1 | $14 |
| Balt USA, LLC | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMPEDE EMBOLIZATION PLUG$3,786
- Indigo System$1,168
- ENROUTE Transcarotid Neuroprotection System$614
- ENROUTE Transcarotid Stent$614
- ENROUTE .014 Guidewire$275
- ENHANCE Transcarotid Peripheral Access Kit$275
- FLOWTRIEVER CATHETER, S$246
- CT THROMBECTOMY SYSTEM KIT$246
- Penumbra System$171
- IN.PACT Admiral$149
- ANGIO-SEAL$138
- METACROSS OTW$138
- GLIDESHEATH SLENDER$138
- V.A.C. VERAFLO$125
- Abre$122
- ENDOCROSS Device$103
- Torus Stent Graft System$103
How this compares
$9,642 in reported general payments places this provider in the 55th percentile of 347 vascular surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $10,386 |
| ClopidogrelClopidogrel Bisulfate | 101 | $1,226 |
| Tramadol Hcl | 18 | $34 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $46 | $10,38612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 347 vascular surgery providers in Texas.
Other vascular surgery in Dallas
- Gregory PearlDallas$2.3M
- Stephen HohmannDallas$499K
- Michael SiahDallas$392K
- Carlos TimaranDallas$231K
- Dennis GableDallas$211K
- Alton BurnsDallas$98K
- John EidtDallas$88K
- Babafemi PrattDallas$87K
- Marc SalhanickDallas$84K
- Bradley GrimsleyDallas$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.